1. Introduction
Glucagon-like peptide-1 (GLP-1) receptor agonists have gradually emerged as one of the more consequential therapeutic developments in contemporary metabolic medicine, largely because of how broadly their effects appear to extend (Wang et al., 2023). Initially developed to address obesity and type 2 diabetes mellitus, these agents were evaluated primarily for their ability to improve glycemic regulation and promote weight loss (Ramracheya et al., 2018). Yet, as evidence accumulated, it became increasingly difficult to view GLP-1 agonists as acting solely within the narrow confines of glucose control. Their physiological reach, it seems, is far wider (Lee & Jun, 2016).
At a basic level, GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient intake (Nauck & Meier, 2018). Its receptors, however, are not restricted to the pancreas. They are distributed across multiple organ systems, including the brain, skeletal muscle, adipose tissue, and bone. Through these pathways, GLP-1 signaling enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and influences satiety and appetite regulation (Lee & Jun, 2016). These mechanisms help explain the well-established benefits observed in diabetes and obesity management. What has drawn more recent attention is the implication that such widespread receptor distribution may position GLP-1 agonists as modulators of broader processes relevant to women’s health and aging .
Maintaining skeletal muscle mass is particularly important for women, especially in the context of weight loss interventions and advancing age, where declines in muscle integrity can undermine functional independence and quality of life (Wang et al., 2023). Preclinical studies suggest that GLP-1 receptor agonists enhance insulin sensitivity within muscle tissue while simultaneously dampening pro-inflammatory signaling pathways, effects that may offer some protection against muscle catabolism (Kong et al., 2023). There is also evidence pointing toward improvements in mitochondrial efficiency, raising the possibility that GLP-1 therapies may support energy balance and endurance at the cellular level (Macedo et al., 2020).Clinical observations, however, complicate this optimistic picture. Although GLP-1 agonists reliably induce fat loss, they are frequently accompanied by reductions in lean mass. In some cases, skeletal muscle accounts for as much as 15–30% of the total weight lost, an outcome that is particularly concerning for women already vulnerable to sarcopenia (Ahmed et al., 2023). These findings have prompted professional bodies to emphasize the importance of pairing pharmacological therapy with resistance training and sufficient protein intake. When integrated thoughtfully, GLP-1 treatment may therefore reshape metabolic health while still allowing room to preserve muscle strength and long-term mobility (Vilarrasa et al., 2024).
Bone health represents another domain in which GLP-1 signaling appears to play a meaningful, if still evolving, role (Mabilleau et al., 2018). Osteoporosis and fracture risk disproportionately affect women, particularly after menopause, making skeletal preservation a central concern in healthy aging. Experimental studies have identified GLP-1 receptor expression in bone-related cells, suggesting that these agents may exert direct effects on bone remodeling processes (Meng et al., 2016). Preclinical findings indicate that GLP-1 agonists can stimulate bone formation while inhibiting resorption, thereby shifting the balance toward skeletal maintenance (Xie et al., 2021).Clinical data, though more limited, are cautiously encouraging. Modest improvements in bone turnover markers and bone mineral density—particularly at vulnerable sites such as the lumbar spine and femoral neck—have been reported in patients receiving GLP-1 therapy (Tanday et al., 2022). Importantly, despite the weight loss typically associated with these agents, fracture risk does not appear to increase significantly. This suggests that GLP-1 agonists may offer a rare combination of metabolic benefit without the expected skeletal penalty, especially when accompanied by adequate calcium and vitamin D intake and regular physical activity (Singh & Singh, 2022).
Beyond musculoskeletal outcomes, cognitive health has emerged as a further area of interest. Neurodegenerative conditions such as Alzheimer’s disease disproportionately affect women, and strategies that support cognitive resilience are increasingly emphasized in aging research (Mahapatra et al., 2022). GLP-1 analogs act centrally to influence appetite and emotional eating behaviors, with secondary benefits for mood and perceived quality of life. More intriguingly, accumulating evidence points to potential neuroprotective effects. GLP-1 signaling has been linked to reductions in oxidative stress, modulation of neuroinflammation, and interference with amyloid-related pathways implicated in cognitive decline (Behl et al., 2020; Kopp et al., 2022). These mechanisms suggest that GLP-1 therapies may contribute not only to metabolic control but also to the preservation of cognitive function over time.It is also increasingly clear that responses to GLP-1 receptor agonists are not uniform across sexes. Women may exhibit distinct therapeutic profiles, shaped in part by hormonal influences such as estrogen, which can modify GLP-1 activity and downstream metabolic effects (Richard et al., 2016). These differences have implications for fat distribution, energy regulation, and possibly reproductive health, underscoring the importance of sex-specific analyses in both research and clinical practice (Rentzeperi et al., 2022). The intersection of endocrinology, metabolism, and reproductive health further highlights the need for tailored treatment strategies rather than one-size-fits-all approaches (Konan et al., 2023).Against this background, the present study seeks to examine how GLP-1 receptor agonists influence muscle integrity and strength preservation among women undergoing pharmacological weight loss therapy. In parallel, it aims to assess their effects on bone density, turnover, and fracture risk, with an emphasis on long-term musculoskeletal health. By focusing on these outcomes together, the study attempts to clarify whether GLP-1 therapies can support not only weight reduction but also the broader goals of functional longevity and healthy aging in women.
